<?xml version='1.0' encoding='utf-8'?>
<document id="29338933"><sentence text="Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole."><entity charOffset="71-83" id="DDI-PubMed.29338933.s1.e0" text="ketoconazole" /><entity charOffset="148-160" id="DDI-PubMed.29338933.s1.e1" text="fesoterodine" /><entity charOffset="165-177" id="DDI-PubMed.29338933.s1.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29338933.s1.e0" e2="DDI-PubMed.29338933.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29338933.s1.e0" e2="DDI-PubMed.29338933.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s1.e0" e2="DDI-PubMed.29338933.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29338933.s1.e1" e2="DDI-PubMed.29338933.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s1.e1" e2="DDI-PubMed.29338933.s1.e2" /></sentence><sentence text="This study was conducted to estimate in vivo inhibition constant (Ki) of ketoconazole on renal P-glycoprotein (P-gp) using human drug-drug interaction (DDI) study result of fesoterodine and ketoconazole"><entity charOffset="73-85" id="DDI-PubMed.29338933.s2.e0" text="ketoconazole" /><entity charOffset="173-185" id="DDI-PubMed.29338933.s2.e1" text="fesoterodine" /><entity charOffset="190-202" id="DDI-PubMed.29338933.s2.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29338933.s2.e0" e2="DDI-PubMed.29338933.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29338933.s2.e0" e2="DDI-PubMed.29338933.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s2.e0" e2="DDI-PubMed.29338933.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29338933.s2.e1" e2="DDI-PubMed.29338933.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s2.e1" e2="DDI-PubMed.29338933.s2.e2" /></sentence><sentence text=" Fesoterodine is a prodrug which is extensively hydrolyzed by non-specific esterases to the active metabolite 5-hydroxymethyl tolterodine (5-HMT)"><entity charOffset="1-13" id="DDI-PubMed.29338933.s3.e0" text="Fesoterodine" /><entity charOffset="110-137" id="DDI-PubMed.29338933.s3.e1" text="5-hydroxymethyl tolterodine" /><entity charOffset="139-144" id="DDI-PubMed.29338933.s3.e2" text="5-HMT" /><pair ddi="false" e1="DDI-PubMed.29338933.s3.e0" e2="DDI-PubMed.29338933.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29338933.s3.e0" e2="DDI-PubMed.29338933.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s3.e0" e2="DDI-PubMed.29338933.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29338933.s3.e1" e2="DDI-PubMed.29338933.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s3.e1" e2="DDI-PubMed.29338933.s3.e2" /></sentence><sentence text=" 5-HMT is then further metabolized via Cytochrome P450 (CYP) 2D6 and CYP3A4"><entity charOffset="1-5" id="DDI-PubMed.29338933.s4.e0" text="5-HMT" /></sentence><sentence text=" It is reported that 5-HMT is a substrate of P-gp whereas fesoterodine is not"><entity charOffset="58-70" id="DDI-PubMed.29338933.s5.e0" text="fesoterodine" /><entity charOffset="21-32" id="DDI-PubMed.29338933.s5.e1" text="5-HMT" /><pair ddi="false" e1="DDI-PubMed.29338933.s5.e1" e2="DDI-PubMed.29338933.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s5.e1" e2="DDI-PubMed.29338933.s5.e0" /></sentence><sentence text=" Renal clearance of 5-HMT is approximately two-times greater than renal glomerular filtration rate"><entity charOffset="20-24" id="DDI-PubMed.29338933.s6.e0" text="5-HMT" /></sentence><sentence text=" This suggests the possibility that renal clearance of 5-HMT involves secretion by P-gp"><entity charOffset="55-59" id="DDI-PubMed.29338933.s7.e0" text="5-HMT" /></sentence><sentence text=" Utilizing the available pharmacokinetic characteristics of fesoterodine and 5-HMT, we estimated in vivo Ki of ketoconazole on P-gp at kidney based on DDI study data using physiologically-based pharmacokinetic approach"><entity charOffset="60-72" id="DDI-PubMed.29338933.s8.e0" text="fesoterodine" /><entity charOffset="77-82" id="DDI-PubMed.29338933.s8.e1" text="5-HMT" /><entity charOffset="111-123" id="DDI-PubMed.29338933.s8.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29338933.s8.e0" e2="DDI-PubMed.29338933.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29338933.s8.e0" e2="DDI-PubMed.29338933.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s8.e0" e2="DDI-PubMed.29338933.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29338933.s8.e1" e2="DDI-PubMed.29338933.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29338933.s8.e1" e2="DDI-PubMed.29338933.s8.e2" /></sentence><sentence text=" The estimated in vivo Ki of ketoconazole for hepatic CYP3A4 (6"><entity charOffset="29-41" id="DDI-PubMed.29338933.s9.e0" text="ketoconazole" /></sentence><sentence text="64 ng/mL) was consistent with the reported values" /><sentence text=" The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2"><entity charOffset="19-31" id="DDI-PubMed.29338933.s11.e0" text="ketoconazole" /></sentence><sentence text="27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo" /><sentence text="" /></document>